| Ms Rosalien Marie Hill, LPN, CWCA | |
|
235 Civic Center Blvd, Houma, LA 70360-5937 | |
| (985) 266-0444 | |
| Not Available |
| Full Name | Ms Rosalien Marie Hill |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 235 Civic Center Blvd, Houma, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801676952 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 30003458 (Louisiana) | Secondary |
| 171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Rosalien Marie Hill, LPN, CWCA 235 Civic Center Blvd, Houma, LA 70360-5937 Ph: () - | Ms Rosalien Marie Hill, LPN, CWCA 235 Civic Center Blvd, Houma, LA 70360-5937 Ph: (985) 266-0444 |
News Archive
Preventable medical errors of various kinds kill at least 200,000 Americans each year, making this the third leading cause of death in the United States, six times as many deaths as from auto accidents. One way to reduce such errors is for consumers to choose the best surgeons. For the first time ever, consumers across the U.S. today have access to ratings of individual surgeons based on outcomes—how often their patients die in hospital or within 90 days of hospital discharge, have serious complications in hospital, or need to be readmitted to a hospital within 90 days of discharge.
Advances in stem cell biology will improve our understanding of degenerative diseases and assist in developing therapies for replacing damaged or diseased parts/tissues.
In Sunday news appearances, GOP presidential nominee Mitt Romney said that if elected, he would dismantle the health care law, but retain some of the more popular provisions, including coverage of pre-existing conditions for those who had had continuous health insurance.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
› Verified 7 days ago